| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
3 |
| Employees |
24 |
| Revenues (TTM) (Millions $) |
2 |
| Net Income (TTM) (Millions $) |
-35 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Oncternal Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. They specialize in the development of novel targeted therapies for the treatment of various types of cancer.
The company focuses on developing therapies that target specific genetic mutations and signaling pathways associated with cancer, with the goal of improving patient outcomes. Their pipeline of investigational drugs includes both small molecule inhibitors and monoclonal antibodies.
Oncternal Therapeutics is particularly focused on developing treatments for hematologic malignancies, such as lymphoma and leukemia, as well as solid tumors. They have ongoing clinical trials for several of their product candidates, and are actively advancing their research and development efforts.
The company's approach involves collaborating with leading academic institutions and utilizing the expertise of their experienced team of scientists and clinicians. Oncternal Therapeutics aims to bring innovative and effective therapies to patients in need, with the ultimate goal of improving lives and fighting cancer.
Company Address: 12230 El Camino Real San Diego 92130 CA
Company Phone Number: 434-1113 Stock Exchange / Ticker: NASDAQ ONCT
|
%
